Weigh Pros and Cons of SGLT2 Inhibitors for Kidney Protection

You'll see more interest in using SGLT2 inhibitors (Invokana, etc) for renal protection in patients with type 2 diabetes.

Earlier findings from CV studies suggest SGLT2 inhibitors may protect the kidneys...probably by lowering intraglomerular pressure.

Now there's evidence in chronic kidney disease...mostly in patients with an eGFR below 60 mL/min.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote